Literature DB >> 18644400

Side-chain modified vitamin D analogs induce rapid accumulation of VDR in the cell nuclei proportionately to their differentiation-inducing potential.

Elzbieta Gocek1, Marek Kiełbiński, Paulina Wyłób, Andrzej Kutner, Ewa Marcinkowska.   

Abstract

1,25-Dihydroxyvitamin D(3) (1,25D) regulates gene transcription through a nuclear vitamin D receptor (VDR) which acts as a ligand-regulated transcription factor. Some structural vitamin D analogs (VDAs) are selective in their biological actions, because they retain cell-differentiating potential, while their calcemic activity is reduced. In this article we have shown that in untreated HL60 cells the expression level of VDR is low, in spite of constant presence of VDR mRNA. Furthermore we have shown that one of the most rapid effects of either 1,25D or VDAs is nuclear accumulation of VDR, which is proportional to the differentiation-inducing potential of given analog. We observed this effect not only in HL60 cells, but also in blast cells isolated from patients with acute myeloid leukemias. After longer incubation time of the cells with various VDAs, the expression levels of VDR have become unrelated to the final differentiation effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644400     DOI: 10.1016/j.steroids.2008.06.010

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  9 in total

Review 1.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

2.  Differential interference of vitamin D analogs PRI-1906, PRI-2191, and PRI-2205 with the renewal of human colon cancer cells refractory to treatment with 5-fluorouracil.

Authors:  Agnieszka Kotlarz; Małgorzata Przybyszewska; Paweł Swoboda; Joanna Miłoszewska; Monika Anna Grygorowicz; Andrzej Kutner; Sergiusz Markowicz
Journal:  Tumour Biol       Date:  2015-10-28

Review 3.  Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy.

Authors:  Philip J Hughes; Ewa Marcinkowska; Elzbieta Gocek; George P Studzinski; Geoffrey Brown
Journal:  Leuk Res       Date:  2009-10-06       Impact factor: 3.156

4.  Diverse Regulation of Vitamin D Receptor Gene Expression by 1,25-Dihydroxyvitamin D and ATRA in Murine and Human Blood Cells at Early Stages of Their Differentiation.

Authors:  Sylwia Janik; Urszula Nowak; Agnieszka Łaszkiewicz; Anastasiia Satyr; Michał Majkowski; Aleksandra Marchwicka; Łukasz Śnieżewski; Klaudia Berkowska; Marian Gabryś; Małgorzata Cebrat; Ewa Marcinkowska
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

5.  Regulation of Leukemic Cell Differentiation through the Vitamin D Receptor at the Levels of Intracellular Signal Transduction, Gene Transcription, and Protein Trafficking and Stability.

Authors:  Elżbieta Gocek; Hanna Baurska; Aleksandra Marchwicka; Ewa Marcinkowska
Journal:  Leuk Res Treatment       Date:  2012-05-14

6.  Differentiation therapy of acute myeloid leukemia.

Authors:  Elzbieta Gocek; Ewa Marcinkowska
Journal:  Cancers (Basel)       Date:  2011-05-16       Impact factor: 6.639

7.  Restored expression of vitamin D receptor and sensitivity to 1,25-dihydroxyvitamin D3 in response to disrupted fusion FOP2-FGFR1 gene in acute myeloid leukemia cells.

Authors:  Aleksandra Marchwicka; Aoife Corcoran; Klaudia Berkowska; Ewa Marcinkowska
Journal:  Cell Biosci       Date:  2016-02-02       Impact factor: 7.133

8.  Biological Evaluation of Double Point Modified Analogues of 1,25-Dihydroxyvitamin D₂ as Potential Anti-Leukemic Agents.

Authors:  Aoife Corcoran; Sharmin Nadkarni; Kaori Yasuda; Toshiyuki Sakaki; Geoffrey Brown; Andrzej Kutner; Ewa Marcinkowska
Journal:  Int J Mol Sci       Date:  2016-02-01       Impact factor: 5.923

9.  1,25(OH)2D3 treatment attenuates high glucose‑induced peritoneal epithelial to mesenchymal transition in mice.

Authors:  Lina Yang; Yi Fan; Xiuli Zhang; Wenyu Huang; Jianfei Ma
Journal:  Mol Med Rep       Date:  2017-07-27       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.